Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:AMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.31-2.2%$5.65$2.90▼$11.16$349.18M0.473.36 million shs761,346 shsAMTAmerican Tower$220.80-0.1%$216.48$172.51▼$243.56$103.35B0.822.50 million shs124,064 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-7.17%-7.56%-34.72%-0.23%-41.18%AMTAmerican Tower-0.22%-0.28%+3.08%+3.69%+12.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.325 of 5 stars3.41.00.00.03.11.70.6AMTAmerican Tower3.9985 of 5 stars2.63.01.73.14.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20313.64% UpsideAMTAmerican Tower 3.11Buy$240.888.93% UpsideCurrent Analyst Ratings BreakdownLatest MX1, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/8/2025AMTAmerican TowerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$250.00 ➝ $260.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/19/2025AMTAmerican TowerBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$255.005/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$240.00 ➝ $250.004/30/2025AMTAmerican TowerWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$230.00 ➝ $240.004/30/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$234.00 ➝ $248.004/30/2025AMTAmerican TowerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$248.00 ➝ $260.004/30/2025AMTAmerican TowerRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$231.00 ➝ $251.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K17,844.20N/AN/A$1.74 per share2.53AMTAmerican Tower$10.13B10.22$11.54 per share19.16$20.64 per share10.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AMTAmerican Tower$2.26B$3.8956.8522.111.6517.34%30.20%4.82%7/29/2025 (Estimated)Latest MX1, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/AN/AN/A7/29/2025Q2 2025AMTAmerican Tower$2.59N/AN/AN/A$2.58 billionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/29/2025Q1 2025AMTAmerican Tower$2.41$2.75+$0.34$2.75$2.54 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.08%N/A174.81%1 YearsLatest MX1, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/15/2025AMTAmerican Towerquarterly$1.703.21%6/13/20256/13/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85AMTAmerican Tower3.430.810.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAMTAmerican Tower4,691468.14 million467.34 millionOptionableMX1, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesAmerican Tower Corporation (NYSE:AMT) Shares Sold by Mar Vista Investment Partners LLC4 hours ago | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Stock Position Raised by Allworth Financial LP5 hours ago | marketbeat.comStratos Wealth Partners LTD. Decreases Position in American Tower Corporation (NYSE:AMT)July 11 at 4:57 AM | marketbeat.comParr Mcknight Wealth Management Group LLC Acquires 2,020 Shares of American Tower Corporation (NYSE:AMT)July 10 at 8:37 AM | marketbeat.comBrown Advisory Inc. Sells 34,723 Shares of American Tower Corporation (NYSE:AMT)July 10 at 5:28 AM | marketbeat.comU.S. Capital Wealth Advisors LLC Cuts Stock Holdings in American Tower Corporation (NYSE:AMT)July 10 at 5:07 AM | marketbeat.comConcurrent Investment Advisors LLC Sells 2,002 Shares of American Tower Corporation (NYSE:AMT)July 10 at 4:45 AM | marketbeat.comAmerican Tower Earnings Preview: What to ExpectJuly 9 at 6:57 PM | msn.comBridges Investment Management Inc. Sells 58,400 Shares of American Tower Corporation (NYSE:AMT)July 9 at 10:15 AM | marketbeat.comNisa Investment Advisors LLC Acquires 28,234 Shares of American Tower Corporation (NYSE:AMT)July 9 at 10:00 AM | marketbeat.comTopsail Wealth Management LLC Purchases Shares of 1,603 American Tower Corporation (NYSE:AMT)July 9 at 9:58 AM | marketbeat.comGreenleaf Trust Acquires 12,933 Shares of American Tower Corporation (NYSE:AMT)July 9 at 8:02 AM | marketbeat.comValeo Financial Advisors LLC Grows Stock Holdings in American Tower Corporation (NYSE:AMT)July 9 at 7:08 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Holdings Raised by Envestnet Asset Management Inc.July 9 at 5:33 AM | marketbeat.comWorld Investment Advisors Sells 1,683 Shares of American Tower Corporation (NYSE:AMT)July 9 at 5:03 AM | marketbeat.comUBS Group Forecasts Strong Price Appreciation for American Tower (NYSE:AMT) StockJuly 8 at 10:17 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Stock Position Lifted by DekaBank Deutsche GirozentraleJuly 8 at 10:15 AM | marketbeat.comAmerican Tower Plans Second Quarter 2025 Earnings Release and Conference CallJuly 8 at 9:21 AM | finance.yahoo.comM&T Bank Corp Reduces Stock Holdings in American Tower Corporation (NYSE:AMT)July 8 at 9:04 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Sold by Strategic Blueprint LLCJuly 8 at 4:52 AM | marketbeat.comAmerican Tower Corporation (NYSE:AMT) Shares Bought by Alpha Cubed Investments LLCJuly 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseInsiders Chase Income and Stability in American Tower—Here’s WhyBy Gabriel Osorio-Mazilli | June 25, 2025View Insiders Chase Income and Stability in American Tower—Here’s WhyMX1, ADR, AMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$4.30 -0.10 (-2.16%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American Tower NYSE:AMT$220.80 -0.22 (-0.10%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
